Information updates

ASCIA COVID-19 update

9 November 2020

In Australia and New Zealand the response to the COVID-19 pandemic has been world leading, with minimal community transmission. However, outbreaks have occurred, and work continues on prevention and treatment of COVID-19, including new vaccines. The ASCIA COVID-19 Working Party will meet in early 2021 to discuss the COVID-19 vaccines and possible allergic reactions. In the meantime we will be monitoring the experiences and responses from authorities in other countries.

COVID-19 Clinical Evidence TaskForce Living Guidelines

The Australian government's National COVID-19 Clinical Evidence TaskForce Living Guidelines are available at and these are updated weekly with the latest research. As a result of these guidelines, ASCIA documents for health professionals about COVID-19 treatments have been “retired”. The ASCIA COVID-19 webpage still includes links to ASCIA information about COVID-19 for patients, consumers and carers. 

ASCIA Representation on RACP COVID-19 Expert Reference Group

ASCIA now has a representative (Dr Theresa Cole) on the Royal Australasian College of Physicians (RACP) COVID-19 Expert Reference Group (ERG), which did not previously include any ASCIA members. This ERG meets fortnightly on Tuesday via Zoom, provides expert advice to the RACP on COVID-19 policy, advocacy issues and organisational matters, and regularly reviews and provides feedback on Government COVID-19 resources.

The RACP has mentioned ASCIA anaphylaxis e-training in a letter they recently sent to the Hon Greg Hunt, Minster for Health regarding the planning for the distribution and roll out of COVID-19 vaccinations. The letter states All vaccine providers should also be trained in rapid emergency treatment of severe allergic reactions (anaphylaxis)1. Reference 1: The Australasian Society of Clinical Immunology and Allergy (ASCIA) provides anaphylaxis e-training.


Mod ASCIA Member
Donate to AIFA
go to NAS website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.